医药中间体

Imatinib 中间体

Imatinib 的 3 个医药中间体。适应症：Chronic Myeloid Leukemia (CML); Acute Lymphoblastic Leukemia (ALL); Hypereosinophilic Syndrome (HES); Myelodysplastic-Myeloproliferative Neoplasms; Chronic Eosinophilic Leukemia (CEL); Myelodysplastic Syndrome (MDS); Dermatofibrosarcoma Protuberans; Systemic Mastocytosis; Chronic Myelogenous Leukemia (CML); Gastrointestinal Stromal Tumor (GIST)。

提交项目全部中间体

关于 Imatinib

原研厂家: Novartis Pharmaceuticals Corp
适应症: Chronic Myeloid Leukemia (CML); Acute Lymphoblastic Leukemia (ALL); Hypereosinophilic Syndrome (HES); Myelodysplastic-Myeloproliferative Neoplasms; Chronic Eosinophilic Leukemia (CEL); Myelodysplastic Syndrome (MDS); Dermatofibrosarcoma Protuberans; Systemic Mastocytosis; Chronic Myelogenous Leukemia (CML); Gastrointestinal Stromal Tumor (GIST)
获批日期: 05/10/2001

可供应中间体

当前列出 Imatinib 的 3 个中间体。可就下方任一产品索取规格、文件或报价。

Imatinib 中间体
产品名称	CAS 号	分子式	物理性质
N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine	152460-10-1	/	/
1-(3-Pyridyl)-3-(dimethylamino)-2-propen-1-one	55314-16-4	/	/
4-[(4-Methylpiperazin -1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3- ylpyrimidin-2-yl)amino]phenyl]benzamide	152459-95-5	/	/

I 字头下的其他品种

Ibrutinib/ Zanubrutinib Iguratimod Imeglimin hydrochloride Indacaterol Maleate Infigratinib Ipatacopan Hydrochloride Ipragliflozin Irinotecan

正在推进 Imatinib 项目？

告诉我们需要覆盖的步骤以及申报规格。我们将确认供应、文件与交期。

提交项目联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →